| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Greenland Mines Ltd. Common Stock
$9.42
+6.19 (+217.19%)
Market Cap
29.93 M
EPS
-6.89
P/E Ratio
-
Value Trade
377.89 K
188.96 %
Week
10.18 %
1 Month
3,071.72 %
3 Month
2,150.9 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
210.94 M
52 Week Range
-
% held by Insiders
9.62 %
% held by Institutions
24 %
Enterprise Value
22.62 M
Total Shares
3.18 M
Short %
22.43 %
Float Shares
114.88 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Greenland Mines Ltd. Common Stock
19Total events
1Upcoming
3Tier-1 (high impact)
2023 – 2026Coverage
Upcoming catalysts 1
TBD
T3Pre IND Meeting
Subscribe to view catalyst details
Event history 2
TBD
▲Patent GrantedIP / Competition
Subscribe to view catalyst details
TBD
▲First Patient DosedKLTO-202Trial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
INSIDER TRANSACTIONSMonthly totals, since 2023
BuysSellsStock price
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GRML
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GRML Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-GRML
Sep 21, 2026▲ +217.2%today
Greenland Mines More Than Doubles Control Position in the Sarfartoq Rare Earth Magnet District in West Greenland
Greenland Mines has significantly expanded its control in the Sarfartoq Rare Earth Magnet District, increasing its project area to approximately 454 km². This expansion follows a review of geological data that suggests further rare earth potential east of the existing deposit. The move is part of a broader strategy to enhance the development of the ST1 deposit, valued at $2.05 billion.
Read more →-GRML
Sep 18, 2026▲ +217.2%today
Greenland Mines Applauds Historic U.S.-Denmark-Greenland Security Agreement, Reinforcing Greenland’s Strategic Importance to the United States
Greenland Mines Ltd has expressed strong support for a new security agreement between the U.S., Denmark, and Greenland. This landmark agreement aims to bolster U.S. security presence in Greenland, highlighting the region's strategic importance. The announcement is expected to foster closer ties and potential economic benefits for Greenland.
Read more →-GRML
Sep 14, 2026Greenland Mines Forms Strategic Advisory Board With Three Industry Leaders to Accelerate Project Development and Western Critical-Minerals Strategy
Greenland Mines Ltd. has established a Strategic Advisory Board comprising three industry leaders to enhance its project development and critical minerals strategy. The board members bring significant expertise in rare earths and mine operations, particularly in Greenland. This initiative aims to support the company's strategic goals, including studies, permitting, and partnerships.
Read more →-GRML
Sep 11, 2026Greenland Mines Provides Progress Update on 2026 Field Programs at Skaergaard and Sarfartoq
Greenland Mines Ltd has announced a progress update on its 2026 field programs at the Skaergaard and Sarfartoq projects. The President of the company highlighted the successful field season achieved by the teams at both locations. This update reflects the company's ongoing commitment to its exploration efforts in Greenland.
Read more →-GRML
Sep 8, 2026Greenland Mines Enters New Era as Rare Earths and Critical Minerals Company, Achieves Full Nasdaq Compliance and Sets Biotech Spin-Off for Q4
Greenland Mines has achieved full compliance with Nasdaq listing requirements, marking a significant milestone for the company. The board is transitioning its focus towards rare earths and critical minerals, with plans for a biotech spin-off scheduled for Q4 2026. The recent acquisition of the Sarfartoq project further strengthens its position in the market.
Read more →-GRML
Aug 26, 2026Sarfartoq Initial Assessment Reports High-Case Sensitivity of up to US$2.05 Billion Pre-Tax NPV
The Sarfartoq project has reported a high-case sensitivity of up to US$2.05 billion pre-tax NPV, indicating significant potential for the development of a Western rare earth supply chain. However, the article notes that financing for magnet plants and separation trains is occurring ahead of the mines that will supply them, highlighting a sequencing issue in project development.
Read more →-GRML
Aug 25, 2026Greenland Rare Earth Project Books Its First Indicated Resource
Greenland Rare Earth Project has successfully transitioned part of its deposit from Inferred to Indicated resources, a significant milestone in its development. This change is crucial as it enhances the project's economic viability and is recognized by regulators under SK 1300. The project is now better positioned for further assessments and potential investment.
Read more →-GRML
Aug 24, 2026Greenland Mines Delivers Landmark S-K 1300 Mineral Resource Estimate for Sarfartoq in Greenland; First-Ever Indicated Resource and First Combined Open Pit/Underground Resource for the Critical Nd-Pr Magnet Rare Earths Project
Greenland Mines has announced a significant S-K 1300 mineral resource estimate for its Sarfartoq project in Greenland. This report, prepared by Tetra Tech and GeoSim, confirms a high-grade resource enriched in valuable rare earth elements such as neodymium and praseodymium. The estimated resource amounts to approximately 40,700 tons, which could supply five years of NdPr demand.
Read more →-GRML
Aug 18, 2026Critical-Minerals Supply Chains Need More Than Mines. Greenland Mines Is Pursuing a North Atlantic Corridor Strategy
Greenland Mines is adopting a North Atlantic Corridor strategy to enhance critical minerals supply chains. The article emphasizes the need for innovative approaches beyond traditional mining to create value in the industry. This strategy aims to redefine how companies operate within the supply chain landscape.
Read more →-GRML
Aug 17, 2026Greenland Fjords Mappedas Skaergaard Advances Marine-Logistics Planning
The article discusses the critical role of seabed mapping in Arctic mining, emphasizing that even high-grade deposits can face delays without proper marine logistics. Greenland Fjords is advancing its marine-logistics planning to facilitate future development studies. This initiative is essential for ensuring efficient shipping routes for Arctic mining operations.
Read more →-GRML
Jul 10, 2026Biotech Division of Greenland Mines Announces Australian Patent Grant for Klotho Gene Therapy Technology for Treatment of Neuromuscular Diseases
Greenland Mines Ltd has received an Australian patent for its Klotho gene therapy technology aimed at treating neuromuscular diseases. The patent, granted by IP Australia, covers technology exclusively licensed by the company's Biotech Division. This development highlights the company's commitment to advancing innovative treatments in the biopharma sector.
Read more →-GRML
Jul 8, 2026A Greenland Precious-and-Critical-Metals Project Just Took a Planning Step Toward Development, With a Roomful of International Experts
Greenland Mines Ltd. has made significant progress in the development of its Skaergaard project by completing a three-day planning workshop. This event gathered over fifteen international experts to create a roadmap for an Initial Assessment and to plan for the 2026 field campaign. The collaboration aims to enhance the project's development trajectory.
Read more →-GRML
Jul 7, 2026Greenland Mines Adds World Class Magmatic Researchers and Greenland Specialists to 2026 Skaergaard Field Campaign
Greenland Mines Ltd has announced the addition of Professor Wolfgang Maier and Associate Professor Kristoffer Szilas to its 2026 field campaign at the Skaergaard project in southeast Greenland. This strategic move aims to bolster the geological exploration and development team, enhancing the company's capabilities in precious and critical metals. The involvement of these world-class researchers is expected to significantly contribute to the project's success.
Read more →-GRML
Jul 6, 2026▲ +7.4%on this newsshared move
The West Wants a Critical-Minerals Supply Chain Outside China. One Nasdaq Company Is Trying to Build a Piece of It in Greenland.
Greenland Mines Ltd. (NASDAQ: GRML) has secured a strategic investment from SRX Global and completed a share-exchange with AnorTech. These moves aim to establish a North Atlantic Critical Metals Corridor, connecting Greenland's resources with allied jurisdictions. This initiative is part of a broader effort to create a critical-minerals supply chain outside of China.
Read more →-GRML
Jun 30, 2026AnorTech and Greenland Mines Close Strategic Share Exchange Transaction
AnorTech Inc. has successfully completed a share exchange transaction with Greenland Mines Ltd. This strategic move, initially announced on June 16, 2026, aims to enhance collaboration and growth opportunities between the two companies. The transaction marks a significant step in their partnership.
Read more →-GRML
Jun 25, 2026▼ -12.1%on this newsshared move
A Drilling Crew, an Icebreaker, and a Path to an Open Pit at Skaergaard
Greenland Mines Ltd. has signed a contract with Nordisk Fundering for a diamond drilling campaign at Skaergaard. The project will involve approximately 7,500 meters of drilling using three rigs in 2026. This initiative aims to transition one of the West's largest palladium-gold-platinum deposits into a development-ready open-pit project.
Read more →-GRML
Jun 25, 2026▼ -8%on this newsshared move
Greenland Mines Concludes Three-Day Technical Workshop to Define and Advance Next Phase of Skaergaard Gold and Critical Metals Project Development
Greenland Mines Ltd has successfully completed a three-day technical workshop aimed at advancing the Skaergaard Gold and Critical Metals Project. The workshop involved multi-disciplinary planning and development efforts to define the next phase of the project. This initiative is crucial for the future development of the project in southeast Greenland.
Read more →-GRML
Jun 22, 2026▲ +10.5%on this news· ran to -22% by day 3shared move
A Greenland Rare Earth Story Is Accelerating as the West Races to Break China’s Magnet Grip
Greenland Mines Ltd. is at the forefront of a significant shift in the rare earth supply chain as the U.S. prepares to ban neodymium-iron-boron magnets sourced from China. Starting January 1, 2027, U.S. defense systems will be prohibited from using these magnets, prompting Western nations to rapidly develop alternative sources. This change could enhance Greenland's position in the global market.
Read more →-GRML
Jun 22, 2026Greenland Mines Signs Drilling Contract with Nordisk Fundering for Expanded 2026 Skaergaard Diamond Drilling Program in Greenland
Greenland Mines Ltd has signed a contract with Nordisk Fundering A/S for diamond drilling as part of its expanded 2026 Skaergaard project. This initiative aims to enhance exploration efforts at the company's 80%-owned site, which focuses on precious and critical metals. The collaboration is expected to bolster the company's operational capabilities in Greenland.
Read more →-GRML
Jun 18, 2026▼ -9.2%on this news· ran to -29% by day 3shared move
Greenland Mines (NASDAQ: GRML) Accelerates Sarfartoq Rare Earths Project Development with Updated S-K 1300 Resource Estimate Program
Greenland Mines Ltd (NASDAQ: GRML) is advancing the Sarfartoq Rare Earths Project by integrating historical resource data with new drilling and technical studies. The company aims to produce an updated Preliminary Economic Assessment (PEA) as part of its development strategy. This initiative is supported by partnerships with Tetra Tech and GeoSim.
Read more →-GRML
Jun 16, 2026A Greenland Critical-Minerals Platform Is Taking Shape — and It Just Pushed Into the Midstream Chokepoint
Greenland Mines Ltd is advancing its critical-minerals platform by investing in the midstream chokepoint, focusing on processing and conversion rather than just extraction. This strategic move aims to enhance Western critical-materials security, positioning the company favorably in the market. The investment reflects a growing recognition of the importance of the entire supply chain in critical minerals.
Read more →-GRML
Jun 16, 2026▲ +12.2%on this newsshared move
Greenland Mines Makes Strategic Investment in AnorTech, Adding Exposure to Sustainable Alumina, High Purity Alumina, and Midstream Critical Minerals Optionality
Greenland Mines Ltd has announced a strategic investment in AnorTech Inc. through a share exchange agreement. This partnership aims to enhance Greenland Mines' exposure to sustainable alumina and high purity alumina, as well as provide optionality in midstream critical minerals. The collaboration is expected to position the company favorably in the growing market for these materials.
Read more →-GRML
May 14, 2026▼ -10.8%on this news
Greenland Mines Ltd (NASDAQ: GRML) Visit greenlandmines.com for more information May 13 - 14, 2026, Toronto From Resource to Corridor: Developing the Skaergaard PGM - Au - V - Ga - Fe - Ti Project in East Greenland for t
Greenland Mines Ltd is focusing on the Skaergaard Project located in Southeast Greenland, which contains a substantial mineral resource of gold, platinum, and palladium. As of February 2026, the gross in-situ metal value of the project is estimated at approximately $68 billion. The company plans to conduct further drilling and technical studies to assess the potential for expansion of the resource and the discovery of economically viable by-products. This project represents a significant part of Greenland Mines’ strategic aim to contribute to the new critical minerals economy.
Read more →-GRML
May 7, 2026Greenland Mines (Nasdaq: GRML) Reports 45–55% PdEq Grade Uplift in Metal-Price Sensitivity at Skaergaard — While Western Critical Minerals Push Hits Inflection Point
Greenland Mines Ltd. (Nasdaq: GRML) reported a 45-55% increase in palladium-equivalent (PdEq) grades at its Skaergaard Project based on a recent metal-price sensitivity analysis. The analysis, conducted by SLR Consulting, indicates substantial potential for the project, which is among the largest undeveloped palladium-gold-platinum deposits globally. The company plans to initiate a fully funded 2026 work program to explore open-pit and bulk-mining scenarios.
Read more →-GRML
May 7, 2026Greenland Mines Reports Up To 45% – 55% Increase in Palladium Equivalent (PdEq) Grades at Skaergaard in Sensitivity Study
Greenland Mines Ltd has reported a substantial increase in palladium equivalent grades at its Skaergaard Project following a metal price sensitivity analysis. The analysis, conducted by SLR Consulting, indicates that higher metal prices could significantly enhance the project's attractiveness, with PdEq grades rising by 45% for Indicated and 55% for Inferred resources. This sensitivity exercise does not constitute an updated Mineral Resource estimate but highlights the project's potential under favorable market conditions.
Read more →-GRML
Mar 23, 2026Greenland Mines Secures Additional 180-Day Period for Nasdaq Bid Price Compliance Extension reflects Company's continued compliance with all other applicable Nasdaq listing requirements Charlotte, North Carolina
Greenland Mines Ltd (Nasdaq: GRML) has been granted an additional 180-day period until September 14, 2026, to regain compliance with Nasdaq's minimum bid price requirement. The extension reflects the company's adherence to all other applicable listing requirements. To regain compliance, Greenland Mines needs to achieve a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. The company remains focused on its strategic mineral resources and its cell and gene therapy initiatives.
Read more →-GRML
Mar 12, 2026Klotho Neurosciences Completes Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to
Klotho Neurosciences has officially rebranded itself as Greenland Mines Ltd and changed its ticker symbol to GRML on Nasdaq. The rebranding reflects the company's strategic focus on natural resources, primarily through the acquisition of Greenland Mines Corp. This acquisition grants it an 80% interest in the Skaergaard Project, known for its vast mineral resources. An investor webcast is scheduled to discuss the acquisition's benefits and future strategies.
Read more →-GRML
Mar 12, 2026Investor Webcast
Greenland Mines Ltd (NASDAQ: GRML) has announced the completion of an acquisition of Greenland Mines, enhancing its portfolio of mineral resources. This move gives GRML access to the Skaergaard Project, a significant undeveloped deposit valued at approximately $68 billion, enabling a new drilling program that aims to double its mineral resource. The company is poised to expand its exploration efforts not only in gold and palladium but also in vanadium and gallium. Management changes include the addition of a new board member, further strengthening the leadership team.
Read more →-GRML
Mar 4, 2026KLOTHO NEUROSCIENCES ACQUIRES GREENLAND MINES CORP., SECURING CONTROL OF A $68 BILLION PALLADIUM, GOLD, PLATINUM, AND CRITICAL MINERAL DEPOSIT IN THE WORLD'S MOST STRATEGICALLY VITAL EMERGING TRADE CORRIDOR Transaction d
Klotho Neurosciences, Inc. has acquired Greenland Mines Corp., gaining control of the Skaergaard Project, a significant deposit of palladium, gold, platinum, and critical minerals valued at approximately $68 billion. This acquisition marks a strategic shift for Klotho, allowing for direct ownership in one of the largest undeveloped mineral deposits globally. The company plans to operate under two divisions focusing on natural resources and cell and gene therapy, intending to enhance both its resource security and biotechnology capabilities. By merging these two sectors, Klotho aims to provide investors with a diversified portfolio amidst growing demand for critical minerals.
Read more →-GRML
Aug 12, 2025Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using AAVnerGene's Platform Technology
Klotho Neurosciences, Inc. has commenced the manufacturing of its KLTO-202 gene therapy candidate in partnership with AAVnerGene. This collaboration utilizes AAVnerGene's innovative platform technology, which enhances the production efficiency and safety of adeno-associated virus vectors. The agreement represents a crucial milestone in Klotho's efforts to develop effective cell and gene therapies for neurodegenerative diseases. AAVnerGene's methods promise to produce therapy candidates faster and with higher purity than traditional techniques, addressing common challenges in gene therapy manufacturing.
Read more →-GRML
Jul 22, 2025Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets.
Klotho Neurosciences, Inc. announced a partnership with AAVnerGene Inc. to enhance the development of its gene therapy assets. This collaboration focuses on improving the efficiency of AAV manufacturing through AAVnerGene's proprietary technologies, which could lead to faster and cost-effective production of treatments for neurological diseases such as Alzheimer's and ALS. Both companies express optimism about the potential to deliver innovative and affordable therapies to patients. The partnership is seen as a strategic move to address current challenges in the gene therapy market.
Read more →-GRML
Jul 16, 2025Klotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity Rules Klotho Neurosciences Maintains Listing on the NASDAQ New York, New York
Klotho Neurosciences, Inc. has confirmed its compliance with NASDAQ's minimum bid price and stockholder equity rules, ensuring its continued listing on the stock exchange. The notification from NASDAQ marks a significant milestone for the company, indicating financial stability. However, the company will be monitored for compliance over the next year, with potential risks concerning equity status. Klotho focuses on developing therapies for neurodegenerative and aging-related diseases.
Read more →-GRML
Jul 10, 2025Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")
Klotho Neurosciences, Inc. has received FDA Orphan Drug Designation for KLTO-202, a gene therapy aimed at treating Amyotrophic Lateral Sclerosis (ALS). This designation provides incentives such as tax credits and potential market exclusivity for seven years, reflecting the importance of developing treatments for this rare and fatal disease. The company is in the process of manufacturing the product and has conducted proof-of-concept studies in animal models. KLTO-202 aims to deliver therapeutic concentrations of the Klotho protein to motor neurons, but it is not yet approved for human use.
Read more →-GRML
Jun 30, 2025Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of
Klotho Neurosciences, Inc. has announced progress in the manufacturing of KLTO-202, a gene therapy aimed at treating amyotrophic lateral sclerosis (ALS). The company licensed the alpha-Klotho gene for development, with animal studies demonstrating its potential neuroprotective effects. The therapy aims to increase local s-KL protein levels to safeguard motor neurons affected by ALS. The company expects to begin clinical trials by the third quarter of next year after completing necessary regulatory requirements.
Read more →-GRML
Jun 16, 2025Klotho Neurosciences Raises Over $11 Million, Retires All Debt, and Exceeds NASDAQ STOCKHOLDERS' Equity Requirement Highlights: Over $11 Million Raised: Proceeds were generated through the exercise of existing warrants.
Klotho Neurosciences, Inc. has raised over $11 million through the exercise of existing warrants, enhancing its financial standing. The company has retired all its outstanding debt, achieving a debt-free balance sheet. Furthermore, Klotho Neurosciences believes it now surpasses the NASDAQ stockholders' equity requirements, demonstrating improved compliance with market regulations. This financial boost aims to support its innovative research in gene and cell therapies for neurodegenerative diseases.
Read more →-GRML
Jun 9, 2025KLOTHO NEUROSCIENCE, INC. ANNOUNCES AN APPROACH TO INCREASE LONGEVITY AND HEALTHY LIFE SPAN - REPLACE A SILENCED GENE CALLED ALPHA-KLOTHO (" -KLOTHO") Recent clinical and pre-clinical studies and analysis indicates the p
Klotho Neurosciences, Inc. has announced findings indicating the potential of increasing lifespan and reducing age-related degeneration through the Klotho gene. Recent studies show that the secreted form of Klotho (s-KL) could enhance lifespan by up to 20% when delivered through a specific vector. The company has secured global rights to utilize s-KL for treating neurodegenerative disorders, presenting a significant opportunity for clinical advancements in age-related medicine. However, risks associated with their business plans and regulatory challenges remain potential hurdles for future progress.
Read more →-GRML
Sep 30, 2024Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO) Renowned Biotech Leader to Contribute Expertise in Neuroscience and Therapeutics Development
Dr. Robert Langer, co-founder of Moderna, has joined the Scientific Advisory Board of Klotho Neurosciences, Inc. This appointment signifies a strong endorsement of Klotho’s mission to develop innovative therapies for neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's disease. Langer will provide critical guidance on scientific and clinical development. Klotho’s proprietary research on the Klotho protein has shown encouraging results in preclinical models, positioning the company as a leader in addressing neurodegenerative disorders.
Read more →-GRML
Jun 20, 2024STRATEGIC ASSET LEASING, INC. 13576 Walnut Street Omaha, NE 68144 Financial Statements and Notes For the Years Ended
Strategic Asset Leasing, Inc. released its financial statements for the years ended December 31, 2023, and 2022, reporting significant losses and raising concerns about its continued viability. The audited financial statements indicate that the company's operations have not been profitable, leading to substantial doubt regarding its ability to continue as a going concern. Key figures include a total asset decrease from $2,539,449 in 2022 to $2,192,706 in 2023 and an increased net loss for 2023 compared to the previous year.
Read more →-GRML
Aug 11, 2023Using Gene Therapy to Address The Aging Process Investor Presentation Q3 2023 Disclaimer 2 This presentation is being furnished solely for the purpose of considering a potential transaction involving Redwoods Acquisition
The presentation discusses a potential transaction between Redwoods Acquisition Corp. and Anew Medical, Inc. focused on utilizing gene therapy to address aging. However, it also emphasizes significant risks associated with the investment, including regulatory hurdles and the speculative nature of the endeavor. Furthermore, it notes the high degree of uncertainty regarding actual financial performance versus forward-looking statements. The information is confidential and intended for accredited investors only.
Read more →-GRML
May 31, 2023Redwoods Acquisition Corp. Announces Receipt of Nasdaq Listing Delinquency Letter and Nasdaq Listing Compliance Determination Letter New York, NY
Redwoods Acquisition Corp. announced receiving and subsequently resolving a Nasdaq compliance notice. The notice was due to the Company's failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2023. However, after filing the necessary documentation, the Company has been determined to be in compliance with Nasdaq Listing Rules, ensuring that its securities remain listed for trading. The Company focuses on mergers and acquisitions, particularly in the carbon neutral and energy storage sectors.
Read more →Older news (3)
- ANEW MEDICAL, INC. Enters Into Definitive Merger Agreement with Redwoods Acquisition Corp . ANEW MEDICAL, INC. ("ANEW") has entered into a definitive business combination agreement with Redwoods Acquisition Corp. (NASDAQMay 30, 2023
- INDEX TO UNAUDITED PRO FORMA FINANCIAL STATEMENT Unaudited Pro Forma Balance Sheet as ofApr 7, 2022
- INDEX TO FINANCIAL STATEMENT Report of Independent Registered Public Accounting Firm F-2 Financial Statement: Balance Sheet F-3 Notes to Financial Statement F-4 F- 1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRApr 4, 2022
Competitive Position
How GRML ranks across every disease it competes inCompetitive Position is a premium feature
See how GRML ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial